Avtozma (tocilizumab-anoh) will be available in both intravenous (IV) and subcutaneous (SC) formulations of various strengths. For IV injectable, it's available in 80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL, while SC injectable is available in 162 mg/0.9 mL. Avtozma has been approved for multiple indications, including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and COVID-19.

The FDA's decision is based on a comprehensive data package and the totality of evidence, including the results from a phase III study demonstrating biosimilarity between Avtozma and reference tocilizumab in patients with moderate to severe active RA. The primary endpoint was met in terms of change from baseline in disease activity score using 28 joints (DAS28)-ESR at Week 24, and the final 1-year results supported comparability in secondary efficacy, pharmacokinetic (PK), safety and immunogenicity results between Avtozma and reference tocilizumab. The clinical results demonstrated that Avtozma and its reference tocilizumab are highly similar and have no clinically meaningful differences in terms of efficacy, safety, pharmacokinetics (PK) and immunogenicity. 

Avtozma has also received a positive opinion from the EMA’s CHMP in Europe [1]. In fact, two other tocilizumab biosimilars — Tyenne and Tofidence — have been approved in Europe and the US during 2023 and 2024, as shown in Table 1.

Two tocilizumab biosimilars, Dr Reddy’s DRL_TC and Mycenax Biotech/Gedeon Richter’s LusiNEX, are in the clinical trial phase.

Related articles
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

EC approves eight biosimilars, eight more await final authorization

References
1. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval for tocilizumab biosimilar Avtozma and filgrastim biosimilar Zefylti [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Mar 5]. Available from: www.gabionline.net/biosimilars/news/ema-recommends-approval-for-tocilizumab-biosimilar-avtozma-and-filgrastim-biosimilar-zefylti
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Mar 5]. Available from: www.gabionline.net/biosimilars/general/biosimilars-approved-in-europe
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in the US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Mar 5]. Available from: www.gabionline.net/biosimilars/general/biosimilars-approved-in-the-us

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2025 Pro Pharma Communications International. All Rights Reserved.